Aniara | Shaping the Future with Innovative Solutions
 Search

Resources

References


APC Factor V Resistance

1. Dahlbäck B et al. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anti-coagulant response to activated protein C: Prediction of a cofactor to activated protein C. Proc Natl Acad Sci 90, 1004-1008. (1993)
2. Svensson P J and Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 330, 517-522 (1994).
3. Bertina R M et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369, 64-67 (1994).
4. Voorberg J et al. Association of idiopathic venous thromboembolism with single point mutation at Arg506 of factor V. Lancet 343, 1535-1536 (1994).
5. Greengard J S et al. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 343, 1361-1362 (1994).
6. Williamson D et al. Factor V Cambridge: A new mutation (Arg306->Thr) associated with resistance to activated protein C. Blood 91, 1140-1144 (1998).
7. Jorquera J I et al. Modified test for activated protein C resistance. Lancet 344, 1162-1163 (1994).
8. Trossaërt M et al. Modified APC resistance assay for patients on oral anticoagulants. Lancet 344, 1709 (1994).
9. Svensson PJ et al. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls. Thromb Haemost 77, 332-335 (1997).
10. Freyburger G et al. Proposal for objective evaluation of the performance of various functional APC-resistance tests in genotyped patients. Thromb Haemost 78, 1360-1365 (1997).
11. Hall C et al. Evaluation of a modified APTT-based method for determination of APC resistance in plasma from patients on heparin or oral anticoagulant therapy. Thromb Res 89, 203-209 (1998).
12. National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3.
13. Freyburger G et al. Response to activated protein C upon storage of whole blood and plasma. Thromb Res 93, 89-95 (1999).
14. National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, NCCLS Document H21-A3; vol. 11 No. 23.
15. National Committee for Clinical Laboratory Standards. EP5-T2. User evaluation of clinical chemistry devises.
16. Hirsh J. Venous Thromboembolism. In: Hoffman R et al (eds) Hematology, Basic Principles and Practice. Churchill Livingstone, 1465-1484 (1991).
17. Goldhaber SZ. Epidemiology of pulmonary embolism and deep vein thrombosis. In: Tuddenham EGD, Bloom AL, Forbes CD, Thomas DP (eds) Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1327-1333 (1994).
18. Thomas DP. Pathogenesis of venous thrombosis. In: Tuddenham EGD, Bloom AL, Forbes CD, Thomas DP (eds) Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone, 1335- 1347 (1994).
19. Heijboer H, Brandjes D, Büller HR et al. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein-thrombosis. New Eng J Med 323, 1512-1516 (1991).
20. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - critical evaluation of laboratory investigation. Thromb Haemost 68, 7-13 (1992).
21. Pabinger I, Brücker S, Kyrle PA et al. Hereditary deficiency of antithrombin, protein C and protein S: prevalence in patients with a history of venous thrombosis and criteria for rational patient screening. Blood Coag Fibr 3, 547-553 (1992).
22a. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: part 1. Thromb Haemost 76, 651-662 (1996).
22b. Lane DA, Mannucci PM, Bauer KA et al. Inherited thrombophilia: part 2. Thromb Haemost 76, 824-834 (1996).
23. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Nat Acad Sci 90, 1004-1008 (1993).
24. Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 82, 1989-1993 (1993).
25. Koster T, Rosendaal F, de Ronde H et al. Venous Thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342, 1503-1506 (1993).
26. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. New Engl J Med 330, 517-522 (1994).
27. Cadroy Y, Sié P, Boneu B. Frequency of a defective response to activated protein C in patients with a history of venous thrombosis. Letters to the Editor. Blood 94, 2008 -2009 (1994).
28. Bertina RM, Koeleman BPC, Koster T et al. Mutation in blood coagulation factor V associated with resistance to Activated Protein C. Nature 369, 64-67 (1994).
29. Voorberg J, Roelse J, Koopman R et al. Association of idiopathic venous thromboembolism with single point- mutation at Arg506 of Factor V. Lancet 343, 1535-1536 (1994).
30. Zöller B, Dahlbäck B. Linkage Between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 343, 1536-1538 (1994).
31. Zöller B, Svensson PJ, He X, Dahlbäck B. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest, 94, 2521-2524 (1994).
32. Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 30, 10363-10370 (1991).
33. Mosher DF. Blood coagulation and fibrinolysis: an overview. Clin Cardiol 13, VI 5-11 (1990).
34. Morrissey JH. Tissue factor.In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 101-118 (1995).
35. Saito H, Kojima T. Factor XII, prekallikrein, and highmolecular-weight kininogen. In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 269-285 (1995).
36. Degen SJF. Prothrombin. In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 75-100 (1995).
37. Ortel TL, Kane WH. Factor V. In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 119-146 (1995).
38. Tuddenham EGD. Factor VIII. In: High KA, Roberts HR (eds) Molecular basis of thrombosis and hemostasis. New York: Marcel Dekker, 167-195 (1995).
39. Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu Rev Biochem 57, 915-956 (1988).
40. Olson ST. Björk I. Regulation of thrombin by antithrombin and heparin cofactor II. In: Berliner LJ (ed) Thrombin: structure and function. New York: Plenum Press 159-217, (1992).
41. Jaffe AE. Endothelial cell structure and function. In: Hoffman R et al (eds) Hematology, basic principles and practice. Churchill Livingstone, 1198-1212 (1991).
42. Dahlbäck B, Stenflo J. A natural anticoagulant pathway: proteins C,S, C4b-binding protein and thrombomodulin. In: Haemostasis and Thrombosis 3rd ed. A L Bloom, C D Forbes, D P Thomas, E G D Tuddenham (eds). Churchill Livingstone, 671-697 (1994).
43. Dahlbäck B. The protein C anticoagulant system: inherited defects as a basis for venous thrombosis. Thromb Res 77, 1-43 (1995).
44. Shen L, Dahlbäck B. Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 269, 18735-18738 (1994).
45. Váradi K, Rosing J, Tans G, Schwarz HP. Influence of factor V and factor Va on APC-induced cleavage of human factor VIII. - Letters to the Editor. Thromb Haemost 73, 730-731 (1995).

Antithrombin

1. Ödegård O R et al. Heparin cofactor activity measured with an amidolytic method. Thromb Res 6, 287-294 (1975).
2. National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3.
3. Zucker S, Cathey M H, West B. Preparation of Quality control specimens for coagulation. Am J Clin Pathol 53, 924-927 (1970).
4. Westgard J O, Barry P L. Cost-effective quality control: Managing the quality and productivity of analytical process. AACC press (1988).
5. National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, NCCLS Document H21-A2; vol. 11 No. 23.
6. Tran T H et al. Influence of Heparin cofactor II (HCII) in the determination of Antithrombin III (AT). Thromb Res 40, 571-576 (1985).
7. Tollefsen D M. Laboratory Diagnosis of Antithrombin and Heparin Cofactor II Deficiency. Seminars in Thromb Haemost 16,162-168 (1990).
8. Andersson N-E et al. New chromogenic AT III activity kit which is insensitive to heparin cofactor II and designed for use on automated instruments.Thromb Haemost 65, 912 (1991).

Factor VIII

1. Van Dieijen G et al. The role of phospholipid and factor VIII in the activation of bovine factor X. J Biol Chem 256, 3433-3442 (1981).
2. Mertens K et al: The role of factor VIII in the activation of blood coagulation factor X by activated factor IX. Thromb Haemost 54, 654-660 (1985).
3. Rosén S. Assay of factor VIII:C with a chromogenic substrate. Scand J Haematol 33, Suppl. 40 139-145 (1984).
4. Rosén S et al: Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost 54, 818-823 (1985).
5. Lethagen S et al: Clinical application of the chromogenic assay of factor VIII in hemophilia A and different variants of von Willebrands disease. Scand J Haematol 37, 448-453 (1986).
6. Tripodi A, Mannucci P M. Factor VIII activity as measured by an amidolytic assay compared with a one-stage clotting assay. Am J Clin Pathol 86, 341-343 (1986).
7. Prowse C et al: Room temperature, microtray chromogenic assay of factor VIII:C. Vox Sang 50, 21-25 (1986).
8. Carlebjörk G et al: A simple and accurate microplate assay for the determination of factor VIII activity. Thromb Res 47, 5-14 (1987).
9. Koster T et al. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152-155 (1995).
10. O'Donnell J et al. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. Thromb Haemost 77, 825-828 (1997).
11. National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3.
12. National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, NCCLS Document H21-A3; vol. 18 No. 20. Dec. 1998

Heparin

1. TW Barrowcliffe et al. An International Standard for Low Molecular Weight Heparin. Thromb Haemostas 60, 1-7 (1988).
2. H A Holm et al. The antithrombotic effect of Heparin in deep venous thrombosis. Relation to four heparin assays. Acta Med Scand 216, 287-293 (1984).
3. HA Holm et al. Heparin assays and bleeding complications in deep venous throm-bosis with particular reference to retroperitonal bleeding. Thromb Haemostas 53, 278-281(1985).
4. E Holmer et al. A new simple chromogenic assay for Heparin and Heparin-like anti-FXa activity in plasma. Thromb Haemostas 54, 29 (1985).
5. AN Teien & M Lie. Evaluation of an amidolytic Heparin assay method: Increased sensitivity by adding purified antithrombin III. Thromb Res 10, 399-410 (1977).
6. H ten Cate et al. Automated amidolytic method for determinating Heparin, a heparinoid, and low-MR Heparin fragment, based on their anti-FXa activity. Clin Chem 30, 860-864 (1984).
7. JJ van Putten et al. Heparin neutralisation during collection and processing of blood inhibited by pyrodoxal 5-phosphate. Haemostasis 14, 253-261 (1984).
8. National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3.
9. National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing andperformance of coagulation assays, NCCLS Document H21-A2; vol. 11 No. 23

Protein C

1. STOCKNER K et al. Protein C activators in snake venoms. Behring Inst Mitt 79, 37-47 (1986).
2. EXNER T and VAASJOKI R. Characterisation and some properties of the Protein C activator from Agkistrodon Contortrix venom. Thromb Haemost 59, 40-44 (1988).
3. PABINGER I. Clinical relevance of Protein C. Blut 53, 63-75 (1986).
4. VINAZZER H and PANGRAZ U. Protein C: Comparison of different assays in normal and abnormal plasma samples. Thromb Res 46, 1-8 (1987).
5. WENDEL H P et al. Aprotinin in therapeutic doses inhibits chromogenic peptide substrate assays for Protein C. Thromb Res 74, 543-548 (1994).
6. National Committee for Clinical Laboratory Standards. Specifications for reagent water used in the clinical laboratory, NCCLS Approved Standard: ASC-3.
7. National Committee for Clinical Laboratory Standards. Collection, transport and processing of blood specimens for coagulation testing and performance of coagulation assays, NCCLS Document H21-A2; vol. 11 No. 23.
8. ZUCKER S, CATHEY M H, WEST B. Preparation of Quality control specimens for coagulation. Am J Clin Pathol 53, 924-927 (1970).
9. WESTGARD J O, BARRY P L. Cost-effective quality control: Managing the quality and productivity of analytical process. AACC press (1988).
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin.
Aniara